Onyda XR (clonidine ER, non-stimulant ADHD)

ADHD in pediatric patients 6 years and older, as monotherapy or adjunct to CNS stimulants. Child and adolescent psychiatry (ADHD).

About Onyda Xr

Onyda XR (clonidine hydrochloride extended-release oral suspension) is manufactured by Tris Pharma and was approved by the US FDA in 2024 for attention-deficit hyperactivity disorder (ADHD) in pediatric patients six years and older, as monotherapy or as adjunct to a CNS stimulant. It is the first FDA-approved liquid extended-release clonidine for paediatric ADHD.

The molecule is a central alpha-2 adrenergic agonist that modulates presynaptic noradrenergic activity. It is a non-stimulant and is not a controlled substance; it is not an amphetamine and is not on any DEA schedule. Paediatricians often reach for clonidine ER precisely because they want an alpha-2 mechanism rather than a stimulant, with the liquid formulation supporting flexible weight-based titration in younger children. Onyda XR is typically dosed in the evening to support sleep onset and next-day attention.

Onyda XR may be accessible to international patients through Named Patient Program or personal-import pathways where it is not yet locally registered.

Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.

How Reserve Meds coordinates Onyda Xr

  1. Patient or treating physician submits a named-patient request.
  2. Clinical team verifies appropriateness of Onyda Xr for the patient and destination country.
  3. Treating physician issues prescription and clinical justification.
  4. Country-specific NPP / personal-import documentation is prepared.
  5. Onyda Xr is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
  6. Shipment is coordinated to the patient's physician or hospital pharmacy (cold-chain where required).

Access by country

Reserve Meds publishes a detailed country deep-dive for Onyda Xr in every market we coordinate. Each page below covers the destination-country regulatory pathway (named-patient framework), real costs in local currency and USD, indicative timelines, physician-credential requirements, and cold-chain handling for the route into that country. Tap any country to read the full deep-dive.

Start a request for Onyda Xr

Submit a 60-second intake. Our clinical team will reach out as our first cohort opens with case-specific feasibility, timeline, and a formal quote.

Request Onyda Xr